Hydralazine Dragees T.O.

Hydralazine Dragees T.O.



T. O. Chemicals


T. O. Chemicals
Concise Prescribing Info
Hydralazine HCl
Combination therapy in HTN & chronic CHF.
Dosage/Direction for Use
50-200 mg depending on indication.
Should be taken with food.
Idiopathic SLE & related diseases. Severe tachycardia & heart failure w/ high cardiac output. Myocardial insufficiency due to mechanical obstruction. Isolated right ventricular heart failure due to pulmonary HTN. Dissecting aortic aneurysm.
Special Precautions
Prolonged treatment especially w/ doses >100 mg/day may provoke SLE-like syndrome mainly in slow acetylators. Periodic urine analysis & determination of anti-nuclear factors are recommended. Suspected or confirmed CAD. Recent MI. Renal impairment, hepatic dysfunction, cerebrovascular disease, surgery. Pregnancy & lactation.
Adverse Reactions
SLE-like syndrome (arthralgia, joint swelling, fever), tachycardia, hypotension, heart failure, nausea, hemolytic anemia, agranulocytosis, hepatitis, glomerulonephritis, acute renal failure.
Drug Interactions
BP-lowering effect may be potentiated by concurrent use of anesth, other antihypertensives, minor tranquilizers, TCAs. Decreased antihypertensive effect when used concomitantly w/ sympathomimetics. Administration shortly before or after diazoxide may give rise to marked hypotension.
ATC Classification
C02DB02 - hydralazine ; Belongs to the class of hydrazinophthalazine derivatives. Used in the treatment of hypertension.
Hydralazine Dragees T.O. tab 50 mg
50 × 10's;500's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in